Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making: A systematic review.

IF 3.5 2区 医学 Q2 ONCOLOGY Ejso Pub Date : 2024-11-15 DOI:10.1016/j.ejso.2024.109463
Luca Boldrini, Diepriye Charles-Davies, Angela Romano, Matteo Mancino, Ilaria Nacci, Huong Elena Tran, Francesco Bono, Edda Boccia, Maria Antonietta Gambacorta, Giuditta Chiloiro
{"title":"Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making: A systematic review.","authors":"Luca Boldrini, Diepriye Charles-Davies, Angela Romano, Matteo Mancino, Ilaria Nacci, Huong Elena Tran, Francesco Bono, Edda Boccia, Maria Antonietta Gambacorta, Giuditta Chiloiro","doi":"10.1016/j.ejso.2024.109463","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Predicting pathological complete response (pCR) from pre or post-treatment features could be significant in improving the process of making clinical decisions and providing a more personalized treatment approach for better treatment outcomes. However, the lack of external validation of predictive models, missing in several published articles, is a major issue that can potentially limit the reliability and applicability of predictive models in clinical settings. Therefore, this systematic review described different externally validated methods of predicting response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) patients and how they could improve clinical decision-making.</p><p><strong>Method: </strong>An extensive search for eligible articles was performed on PubMed, Cochrane, and Scopus between 2018 and 2023, using the keywords: (Response OR outcome) prediction AND (neoadjuvant OR chemoradiotherapy) treatment in 'locally advanced Rectal Cancer'.</p><p><strong>Inclusion criteria: </strong>(i) Studies including patients diagnosed with LARC (T3/4 and N- or any T and N+) by pre-medical imaging and pathological examination or as stated by the author (ii) Standardized nCRT completed. (iii) Treatment with long or short course radiotherapy. (iv) Studies reporting on the prediction of response to nCRT with pathological complete response (pCR) as the primary outcome. (v) Studies reporting external validation results for response prediction. (vi) Regarding language restrictions, only articles in English were accepted.</p><p><strong>Exclusion criteria: </strong>(i) We excluded case report studies, conference abstracts, reviews, studies reporting patients with distant metastases at diagnosis. (ii) Studies reporting response prediction with only internally validated approaches.</p><p><strong>Data collection and quality assessment: </strong>Three researchers (DC-D, FB, HT) independently reviewed and screened titles and abstracts of all articles retrieved after de-duplication. Possible disagreements were resolved through discussion among the three researchers. If necessary, three other researchers (LB, GC, MG) were consulted to make the final decision. The extraction of data was performed using the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) template and quality assessment was done using the Prediction model Risk Of Bias Assessment Tool (PROBAST).</p><p><strong>Results: </strong>A total of 4547 records were identified from the three databases. After excluding 392 duplicate results, 4155 records underwent title and abstract screening. Three thousand and eight hundred articles were excluded after title and abstract screening and 355 articles were retrieved. Out of the 355 retrieved articles, 51 studies were assessed for eligibility. Nineteen reports were then excluded due to lack of reports on external validation, while 4 were excluded due to lack of evaluation of pCR as the primary outcome. Only Twenty-eight articles were eligible and included in this systematic review. In terms of quality assessment, 89 % of the models had low concerns in the participants domain, while 11 % had an unclear rating. 96 % of the models were of low concern in both the predictors and outcome domains. The overall rating showed high applicability potential of the models with 82 % showing low concern, while 18 % were deemed unclear.</p><p><strong>Conclusion: </strong>Most of the external validated techniques showed promising performances and the potential to be applied in clinical settings, which is a crucial step towards evidence-based medicine. However, more studies focused on the external validations of these models in larger cohorts is necessary to ensure that they can reliably predict outcomes in diverse populations.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":" ","pages":"109463"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejso.2024.109463","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Predicting pathological complete response (pCR) from pre or post-treatment features could be significant in improving the process of making clinical decisions and providing a more personalized treatment approach for better treatment outcomes. However, the lack of external validation of predictive models, missing in several published articles, is a major issue that can potentially limit the reliability and applicability of predictive models in clinical settings. Therefore, this systematic review described different externally validated methods of predicting response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) patients and how they could improve clinical decision-making.

Method: An extensive search for eligible articles was performed on PubMed, Cochrane, and Scopus between 2018 and 2023, using the keywords: (Response OR outcome) prediction AND (neoadjuvant OR chemoradiotherapy) treatment in 'locally advanced Rectal Cancer'.

Inclusion criteria: (i) Studies including patients diagnosed with LARC (T3/4 and N- or any T and N+) by pre-medical imaging and pathological examination or as stated by the author (ii) Standardized nCRT completed. (iii) Treatment with long or short course radiotherapy. (iv) Studies reporting on the prediction of response to nCRT with pathological complete response (pCR) as the primary outcome. (v) Studies reporting external validation results for response prediction. (vi) Regarding language restrictions, only articles in English were accepted.

Exclusion criteria: (i) We excluded case report studies, conference abstracts, reviews, studies reporting patients with distant metastases at diagnosis. (ii) Studies reporting response prediction with only internally validated approaches.

Data collection and quality assessment: Three researchers (DC-D, FB, HT) independently reviewed and screened titles and abstracts of all articles retrieved after de-duplication. Possible disagreements were resolved through discussion among the three researchers. If necessary, three other researchers (LB, GC, MG) were consulted to make the final decision. The extraction of data was performed using the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) template and quality assessment was done using the Prediction model Risk Of Bias Assessment Tool (PROBAST).

Results: A total of 4547 records were identified from the three databases. After excluding 392 duplicate results, 4155 records underwent title and abstract screening. Three thousand and eight hundred articles were excluded after title and abstract screening and 355 articles were retrieved. Out of the 355 retrieved articles, 51 studies were assessed for eligibility. Nineteen reports were then excluded due to lack of reports on external validation, while 4 were excluded due to lack of evaluation of pCR as the primary outcome. Only Twenty-eight articles were eligible and included in this systematic review. In terms of quality assessment, 89 % of the models had low concerns in the participants domain, while 11 % had an unclear rating. 96 % of the models were of low concern in both the predictors and outcome domains. The overall rating showed high applicability potential of the models with 82 % showing low concern, while 18 % were deemed unclear.

Conclusion: Most of the external validated techniques showed promising performances and the potential to be applied in clinical settings, which is a crucial step towards evidence-based medicine. However, more studies focused on the external validations of these models in larger cohorts is necessary to ensure that they can reliably predict outcomes in diverse populations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部晚期直肠癌患者新辅助治疗的反应预测--改善决策:系统综述。
背景:根据治疗前或治疗后的特征预测病理完全反应(pCR)对于改善临床决策过程和提供更个性化的治疗方法以获得更好的治疗效果具有重要意义。然而,在一些已发表的文章中,预测模型缺乏外部验证,这是一个主要问题,可能会限制预测模型在临床环境中的可靠性和适用性。因此,本系统性综述介绍了预测局部晚期直肠癌(LARC)患者对新辅助化放疗(nCRT)反应的不同外部验证方法,以及这些方法如何改善临床决策:使用关键词:"局部晚期直肠癌 "的(反应或结果)预测和(新辅助或化放疗)治疗,对2018年至2023年期间在PubMed、Cochrane和Scopus上符合条件的文章进行了广泛搜索:(i) 包括经医学影像和病理检查前诊断为局部晚期直肠癌(T3/4 和 N- 或任何 T 和 N+)的患者或作者声明的患者的研究 (ii) 已完成标准化 nCRT。(iii) 长程或短程放疗。(iv) 报告以病理完全反应(pCR)为主要结果的 nCRT 反应预测的研究。(v) 报告反应预测外部验证结果的研究。(vi) 关于语言限制,只接受英文文章:(i) 我们排除了病例报告研究、会议摘要、综述以及报告诊断时有远处转移患者的研究。(数据收集和质量评估:三位研究人员(DC-D、FB、HT)独立审查并筛选了去重后检索到的所有文章的标题和摘要。三位研究人员通过讨论解决了可能存在的分歧。如有必要,还咨询了其他三位研究人员(LB、GC、MG),以做出最终决定。数据提取采用预测模型研究系统性综述关键评估和数据提取清单(CHARMS)模板,质量评估采用预测模型偏倚风险评估工具(PROBAST):结果:从三个数据库中共识别出 4547 条记录。在排除了 392 条重复结果后,4155 条记录经过了标题和摘要筛选。经过标题和摘要筛选,共排除了 380 篇文章,检索到 355 篇文章。在检索到的 355 篇文章中,有 51 项研究通过了资格评估。其中 19 篇因缺乏外部验证报告而被排除,4 篇因缺乏 pCR 作为主要结果的评估而被排除。只有 28 篇文章符合条件并被纳入本系统综述。在质量评估方面,89%的模型在参与者领域的关注度较低,11%的模型评级不明确。96%的模型在预测因素和结果领域的关注度都较低。总体评级显示,82%的模型关注度较低,18%的模型被认为不明确,这些模型具有很高的适用性潜力:大多数外部验证技术都显示出良好的性能和应用于临床的潜力,这是实现循证医学的关键一步。然而,有必要开展更多研究,重点关注这些模型在更大群体中的外部验证,以确保它们能可靠地预测不同人群的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ejso
Ejso 医学-外科
CiteScore
6.40
自引率
2.60%
发文量
1148
审稿时长
41 days
期刊介绍: JSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery. The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.
期刊最新文献
Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making: A systematic review. The influence of treatment intervals on prognosis in young breast cancer patients: Insights from the French National cohort The efficacy of immediate lymphatic reconstruction after axillary lymph node dissection – A meta-analysis Establishment a nomogram model for preoperative prediction of the risk of cholangiocarcinoma with microvascular invasion Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1